Piper Sandler adjusted its stance on Amphastar Pharmaceuticals (NASDAQ:AMPH), downgrading the company's stock rating from Overweight to Neutral and significantly reducing the price target to $36.00 ...

Fintel reports that on February 4, 2025, Piper Sandler downgraded their outlook for Amphastar Pharmaceuticals (NasdaqGS:AMPH) ...

Piper Sandler downgraded Amphastar (AMPH) to Neutral from Overweight with a price target of $36, down from $66. The firm noted that shares of ...

In a report released today, Jason Gerberry from Bank of America Securities reiterated a Hold rating on Amphastar Pharmaceuticals (AMPH – ...

Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, CA. This small manufacturing pharma concern is focused on making and distributing generic and proprietary injectable ...

Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products ...

Detailed price information for Amphastar Pharma (AMPH-Q) from The Globe and Mail including charting and trades.

Xeris Pharmaceuticals has teamed up with the American Diabetes Association (ADA) to raise awareness of the importance of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...